Table 1.
Summary of anti-HPV geometric mean titers and seroconversion percentage over timea
| Response | Study time | n | GMT (mMU/ml) | 95% CI | m | Seroconversion (%) | 95% CI |
|---|---|---|---|---|---|---|---|
| Anti-HPV-6 | Day 1 | 1,092 | <7 | <7, <7 | 0 | 0.0 | 0.0, 0.3 |
| Mo 7 | 1,092 | 447.6 | 422.6, 474.1 | 1,080 | 98.9 | 98.1, 99.4 | |
| Mo 24 | 941 | 79.8 | 75.8, 84.1 | 855 | 90.9 | 88.8, 92.6 | |
| Mo 36 | 847 | 71.5 | 67.5, 75.8 | 753 | 88.9 | 86.6, 90.9 | |
| Anti-HPV-11 | Day 1 | 1,092 | <8 | <8, <8 | 0 | 0.0 | 0.0, 0.3 |
| Mo 7 | 1,092 | 624.0 | 594.1, 655.4 | 1,083 | 99.2 | 98.4, 99.6 | |
| Mo 24 | 941 | 94.6 | 90.0, 99.5 | 900 | 95.6 | 94.1, 96.9 | |
| Mo 36 | 847 | 82.6 | 78.3, 87.1 | 796 | 94.0 | 92.2, 95.5 | |
| Anti-HPV-16 | Day 1 | 1,135 | <11 | <11, <11 | 0 | 0.0 | 0.0, 0.3 |
| Mo 7 | 1,135 | 2,404.3 | 2,272.2, 2,544.0 | 1,121 | 98.8 | 97.9, 99.3 | |
| Mo 24 | 979 | 342.7 | 324.7, 361.7 | 970 | 99.1 | 98.3, 99.6 | |
| Mo 36 | 877 | 293.3 | 276.5, 311.2 | 859 | 97.9 | 96.8, 98.8 | |
| Anti-HPV-18 | Day 1 | 1,174 | <10 | <10, <10 | 0 | 0.0 | 0.0, 0.3 |
| Mo 7 | 1,174 | 402.3 | 380.2, 425.7 | 1,143 | 97.4 | 96.3, 98.2 | |
| Mo 24 | 1,011 | 38.4 | 36.0, 41.0 | 630 | 62.3 | 59.2, 65.3 | |
| Mo 36 | 905 | 33.1 | 30.9, 35.4 | 516 | 57.0 | 53.7, 60.3 |
a
The estimated GMTs and associated CIs are calculated using an analysis of variance model with a term for vaccination group. Seroconversion percent is calculated as 100 × (m/n). The seroconversion CIs are computed based on exact methods. n, number of subjects contributing to the analyses; m, number of subjects with the indicated response.